28 Views

CRT 2026

Beyond the Guidelines

Session:: Beyond the Guidelines | De-Escalation of Antiplatelet Therapy [Non-CME]

When can You Drop Triple Therapy After PCI?

Monday, March 9, 2026

4:32 PM - 4:40 PM EST

Location: Spotlight Theater

Speaker(s)

C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Amgen, Chiesi, Angel/Avertix Medical, Anthos Therapeutics, Janssen Pharmaceuticals, Johnson & Johnson Corporation, Bayer Corporation, Corsear, MashUp MD, Bioclinica, MD Magazine, Boehringer Ingelheim, Merck, Boston Clinical Research Institute, MjHeal: Consulting Fees (e.g., advisory boards) (Ongoing); HeartBeam, nference, Flow Therapy, Celecor, Fortress Biotech, TribeMD (Co-Founder), Generable and Lexaria: Stock Options [in privately held companies] (Ongoing); Johnson & Johnson Corporation, CSL Behring, SCAD Alliance, NACAM Trial (Sub-award - 5R01HL151996-05), and Janssen Pharmaceuticals.: Grant/Research Support (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing)

Disclosure(s):

C. Michael Gibson, MD: Amgen, Chiesi, Angel/Avertix Medical, Anthos Therapeutics, Janssen Pharmaceuticals, Johnson & Johnson Corporation, Bayer Corporation, Corsear, MashUp MD, Bioclinica, MD Magazine, Boehringer Ingelheim, Merck, Boston Clinical Research Institute, MjHeal: Consulting Fees (e.g., advisory boards) (Ongoing); HeartBeam, nference, Flow Therapy, Celecor, Fortress Biotech, TribeMD (Co-Founder), Generable and Lexaria: Stock Options [in privately held companies] (Ongoing); Johnson & Johnson Corporation, CSL Behring, SCAD Alliance, NACAM Trial (Sub-award - 5R01HL151996-05), and Janssen Pharmaceuticals.: Grant/Research Support (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing)